布地奈德不同给药方式治疗慢性鼻-鼻窦炎的临床效果观察  

Observation on the Clinical Effects of Different Administrations of Budesonide in the Treatment of Chronic Rhinosinusitis

作　　者：戴如立[1] 邓华瑞 骆映峰[1] 

机构地区：[1]广东省农垦中心医院,广东湛江524002

出　　处：《临床医学工程》2018年第1期89-90,共2页Clinical Medicine & Engineering

摘　　要：目的探讨布地奈德不同给药方式治疗慢性鼻-鼻窦炎的临床效果。方法选取我院2015年9月至2016年12月收治的慢性鼻-鼻窦炎患者86例,随机分为A组和B组各43例。A组给予布地奈德雾化吸入治疗,B组给予布地奈德鼻喷雾剂治疗。比较两组患者的症状评分(VAS评分、Lund-Kennedy评分)、病情控制情况及不良反应情况。结果治疗前,两组患者的症状评分比较差异均无统计学意义(P>0.05);治疗后,两组患者的症状评分均有所改善,且A组的症状评分均明显低于B组,差异有统计学意义(P<0.05)。A组的病情控制率为95.35%,显著高于B组的81.40%(P<0.05)。两组均未出现严重不良反应,且不良反应发生率比较差异无统计学意义(P>0.05)。结论布地奈德雾化吸入治疗慢性鼻-鼻窦炎的效果优于鼻喷雾剂,安全性较高,值得推广。Objective To explore the clinical effects of different administrations of budesonide in the treatment of chronic rhinosinusitis. Methods 86 cases of patients with chronic rhinosinusitis admitted to our hospital from September 2015 to December 2016 were selected and randomly divided into group A and group B, with 43 cases in each group. Group A received budesonide atomization inhalation, while group B was treated with budesonide nasal spray. The symptom scores （VAS score and Lund-Kennedy score）, disease control and adverse reactions were compared between two groups. Results Before treatment, no statistical difference was found in the symptom scores between two groups （P 〉0.05）. After treatment, the symptom scores of both groups improved, and the symptom scores of group A were significantly lower than those of group B, with statistical difference （P 〈0.05）. The disease control rate of group A was 95.35%, significantly higher than 81.40% of group B （P〈0.05）. No serious adverse reactions was found in two groups, and no statistical difference was found in the incidence of adverse reactions between two groups （P〉0.05）. Conclusions Budesonide atomization inhalation in the treatment of chronic rhinosinusitis has better effect and higher safety compared with nasal spray, which is worthy of promotion.

关 键 词：慢性鼻-鼻窦炎 布地奈德 雾化吸入 鼻喷雾剂 

分 类 号：R765.41[医药卫生—耳鼻咽喉科]